Category Archives: Internal Medicine

Nizoral ketoconazole Drug Safety Communication

Share

Nizoral (ketoconazole): Drug Safety Communication – Potentially Fatal Liver Injury, Risk of Drug Interactions and Adrenal Gland Problems AUDIENCE: Internal Medicine, Infectious Disease ISSUE: FDA is taking several actions related to Nizoral (ketoconazole) oral tablets, including limiting the drug’s use, … Continue reading

Share
Posted in FDA 2013, FDA Safety Communication, Infectious Disease, Internal Medicine | Tagged , , , , , , , , | Comments Off on Nizoral ketoconazole Drug Safety Communication

Incivek telaprevir Drug Safety Communication

Share

Incivek (telaprevir) In Combination with Drugs Peginterferon Alfa and Ribavirin (Incivek Combination Treatment): Drug Safety Communication – Serious Skin Reactions   AUDIENCE: Internal Medicine, Gastroenterology, Dermatology ISSUE: FDA received reports of serious skin reactions, some fatal, in patients taking the … Continue reading

Share
Posted in Dermatology, FDA Label Change, FDA Safety Communication, Gastroenterology, Internal Medicine | Tagged , , , , , , , , , | Comments Off on Incivek telaprevir Drug Safety Communication

Xyrem sodium oxybate Drug Safety Communication

Share

Xyrem (sodium oxybate): Drug Safety Communication – Warning Against Use With Alcohol or Drugs Causing Respiratory Depression AUDIENCE: Neurology, Internal Medicine, Patient ISSUE: FDA reminded healthcare professionals and patients that the combined use of Xyrem (sodium oxybate) with alcohol or … Continue reading

Share
Posted in FDA 2012, FDA Safety Communication, Internal Medicine, Neurology, Patients | Tagged , , , , , , | Comments Off on Xyrem sodium oxybate Drug Safety Communication

Ampyra dalfampridine drug risks

Share

Drug Safety Communication – Seizure Risk for Multiple Sclerosis Patients AUDIENCE: Neurology, Internal Medicine ISSUE: FDA is updating health care professionals and the public about the risk of seizures in patients with multiple sclerosis (MS) who are starting Ampyra (dalfampridine). … Continue reading

Share
Posted in FDA 2012, FDA Safety Communication, FDA Warning, Internal Medicine, Neurology | Tagged , , , , , , , , , , | Comments Off on Ampyra dalfampridine drug risks

Aliskiren containing Medications Drug Safety Comunication

Share

Aliskiren-containing Medications: Drug Safety Comunication – New Warning and Contraindication including: Amturnide (aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide) Tekturna (aliskiren hemifumarate) Tekturna HCT (aliskiren hemifumarate and hydrochlorothiazide) Tekamlo (aliskiren hemifumarate and amlodipine besylate) Valturna (aliskiren hemifumarate and valsartan). Valturna will … Continue reading

Share
Posted in Endocrinology, FDA 2012, FDA Safety Communication, Internal Medicine, Pharmacy | Tagged , , , , , , , , , , , , , , , , | Comments Off on Aliskiren containing Medications Drug Safety Comunication